Alpha Tau Medical Ltd.
$8.11
0%
2026-04-21 06:29:00
www.alphatau.com
NCM: DRTS
Explore Alpha Tau Medical Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$706.72 M
Current Price
$8.11
52W High / Low
$8.6 / $2.5
Stock P/E
—
Book Value
$0.88
Dividend Yield
—
ROCE
-44.45%
ROE
-61%
Face Value
—
EPS
$-0.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
121
Beta
1.05
Debt / Equity
17.8
Current Ratio
7.45
Quick Ratio
7.45
Forward P/E
-17.12
Price / Sales
—
Enterprise Value
$582.19 M
EV / EBITDA
-14.18
EV / Revenue
—
Rating
None
Target Price
$9.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Intellia Therapeutics, Inc. | $15.21 | — | $1.8 B | — | -59.74% | -53.48% | $28.25 / $6.8 | $5.77 |
| 2. | Incyte Corporation | $97.69 | 15.26 | $19.46 B | — | 24.67% | 29.87% | $112.29 / $56.13 | $26.04 |
| 3. | Jupiter Neurosciences, Inc. | $0.46 | — | $15.86 M | — | -73.72% | -7.39% | $3.33 / $0.31 | $0 |
| 4. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 5. | MannKind Corporation | $2.92 | 135.49 | $907.36 M | — | 7.49% | -9.03% | $6.51 / $2.23 | $-0.17 |
| 6. | Vanda Pharmaceuticals Inc. | $6.99 | — | $417.3 M | — | -43.97% | -50.93% | $9.94 / $3.81 | $5.54 |
| 7. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -12.6 M | -10.73 M | -9.65 M | -9.31 M | -10.27 M |
| Net Profit | -12.14 M | -11.69 M | -10.11 M | -8.69 M | -9.48 M |
| EPS in Rs | -0.14 | -0.13 | -0.11 | -0.1 | -0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -42.29 M | -36.04 M | -35.68 M | -32.14 M |
| Net Profit | -42.63 M | -31.75 M | -29.16 M | -33.76 M |
| EPS in Rs | -0.48 | -0.36 | -0.33 | -0.38 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 105.65 M | 86.2 M | 107.39 M | 120.15 M |
| Total Liabilities | 28.55 M | 23.54 M | 22.91 M | 14.49 M |
| Equity | 77.1 M | 62.67 M | 84.47 M | 105.66 M |
| Current Assets | 78.3 M | 64.23 M | 85.76 M | 106.48 M |
| Current Liabilities | 10.51 M | 8.68 M | 7.1 M | 4.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -26.68 M | -19.78 M | -17.96 M | -23.88 M |
| Investing CF | -20.59 M | 20.77 M | 18.68 M | -89.94 M |
| Financing CF | 45.77 M | 0.03 M | 5.3 M | 96.91 M |
| Free CF | -32.76 M | -22.02 M | -24.36 M | -24.78 M |
| Capex | -6.08 M | -2.24 M | -6.4 M | -0.9 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -8.89% | 13.64% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.